clinical trial · NCT02915705
Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH
Kyowa Kirin, Inc.·phase3·completed·n = 61
X-Linked HypophosphatemiaburosumabOral Phosphate Supplementactive vitamin D
brief summary
The primary objective of this study is to evaluate the effect of KRN23 (burosumab) therapy in improving rickets in children with XLH compared with active control (oral phosphate/active vitamin D).
started
Sep 8, 2016
primary completion
Feb 12, 2018
completion
Jul 15, 2019
last updated
Aug 29, 2024
official title
A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol